Others are classified as HER2-positive (they express the HER2 receptor tyrosine kinase) against which anti-HER2 targeted therapies are applied, and triple-negative breast cancer (TNBC, due to the absence of ER, progesterone and HER2 receptors), which has the worst prognosis and lacks an effective targeted therapy (2–4). Here, ERBB2 is linked to triple-negative breast carcinoma.